BUILD YOUR REPORT

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 5/5

BUILD YOUR REPORT
Progress Date advice Recommendation Type of limitation
Type of limitation
- - -
Rationale and comments Indications Classification Orphan drug
UK - NICE
HTA Reimbursement
France - TC
HTA Reimbursement
GERMANY - GBA
HTA Reimbursement
ITALY
HTA Reimbursement
SPAIN
HTA Reimbursement
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery Additional range
TIMELINES Close all timelines
30 Jul 2018 MA date
HTA
HTA

Rationale and Comments

Type of limitation Recommended with limitations
Access scheme
PAS
  • Increased Overall Survival vs everolimus
  • Improved QoL
  • Some uncertainty in the economic analysis, but acceptable for an orphan equivalent medicine

Reimb
05 Oct
27 Dec
HTA

Rationnel / Commentaires

Type of limitation Recommended
  Obtenue Demandée SMR
En monothérapie dans le traitement adjuvant des patients adultes atteints d’un mélanome avec atteinte des ganglions lymphatiques ou une maladie métastatique, et ayant subi une résection complète
III III important
Comparaison En stratégie thérapeutique
  • Efficacité/effets indésirables important en termes de réduction de risque de récidive
  • Moins d’événements indésirables graves
  • Besoin médical important

Rationnel / Commentaires

Type of limitation Recommended
  Obtenue Demandée SMR
En monothérapie dans le traitement adjuvant des patients adultes atteints d’un mélanome avec atteinte des ganglions lymphatiques ou une maladie métastatique, et ayant subi une résection complète
III III important
Comparaison En stratégie thérapeutique
  • Efficacité/effets indésirables important en termes de réduction de risque de récidive
  • Moins d’événements indésirables graves
  • Besoin médical important

Rationnel / Commentaires

Type of limitation Recommended
  Obtenue Demandée SMR
En monothérapie dans le traitement adjuvant des patients adultes atteints d’un mélanome avec atteinte des ganglions lymphatiques ou une maladie métastatique, et ayant subi une résection complète
III III important
Comparaison En stratégie thérapeutique
  • Efficacité/effets indésirables important en termes de réduction de risque de récidive
  • Moins d’événements indésirables graves
  • Besoin médical important
Reimb
HTA
HTA

Reimb
HTA

Reimb
Agency Total delay (days)
NICE 144
SMC
TC
CEESP 86
GBA
TLV 144
NCPE 105
pCODR
2018
2019
Accepted Restricted Rejected
Withdrawn Suspended Expired Ongoing
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification
In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
[...]
New indication
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Apraisal process

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range

Refine search 3/3

Early access

Nice decision

Approuved decision

View selection

Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Progress Date advice Recommendation Type of limitation Rationale and comments Indications Classification Indications Classification Indications Classification Classification
In progress

2017-08-15

22/05/2013 Accepted
line Specificity Administration
- - -
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

15/11/2012 Accepted Recommended
with limitations
- Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

09/12/2011 Accepted Recommended
with limitations
-
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
  • Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)
New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
In progress

2017-08-15

09/12/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) New indication In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range
Published

Jul.26,2017

30/09/2011 Accepted Recommended
with limitations
- Rivaroxaban for the prevention of venous thromboembolismafter total hip or total knee replacement in adults New product In progress

2017-08-15

22/05/2013 Accepted Recommended
with limitations
- Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome Additional range Additional range